Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)
Michael Bauer(Jena University Hospital), A. Weyland(Carl von Ossietzky Universität Oldenburg), Ingmar Lautenschläger(Universitätsmedizin Göttingen), Markus Loeffler(Leipzig University), Axel Nierhaus(Universität Hamburg), Lorenz Reill(Vivantes Klinikum), Stephan Weber(Statistisches Bundesamt), Anja Diers(Klinikum Oldenburg), Matthias Gründling(Universitätsmedizin Greifswald), Gernot Marx(RWTH Aachen University), Niels C. Riedemann(Inflarx (Germany)), Konrad Reinhart(Charité - Universitätsmedizin Berlin), Stefan Kluge(Universität Hamburg), Achim Jörres(Statistisches Bundesamt), Onnen Moerer(Universitätsmedizin Göttingen), Philipp Simon(University Hospital Leipzig), Renfeng Guo, Norbert Weiler, Ulrich Jaschinski(University Hospital Augsburg), Frank Bloos(Jena University Hospital), Tim Philipp Simon
Cited by 36
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
|Intensive Care Medicine|2007|4.9k
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008
|Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)|2008|3.9k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k